Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jun 1;79(11):2798-2804.
doi: 10.1158/0008-5472.CAN-18-3402. Epub 2019 May 20.

Promises and Pitfalls of Using Liquid Biopsy for Precision Medicine

Affiliations
Review

Promises and Pitfalls of Using Liquid Biopsy for Precision Medicine

Giovanna Rossi et al. Cancer Res. .

Abstract

New sensitive assays are currently available for the detection of circulating tumor DNA (ctDNA) and circulating tumor cells (CTC). However, there remains a need for standardization of preanalytical issues and cross-platform comparison studies. Liquid biopsies are being evaluated for treatment selection, for monitoring disease response and resistance, for tracking minimal residual disease, and for cancer diagnosis. Multiple studies are underway to assess the clinical utility of CTC and ctDNA in different settings (treatment-naïve vs. resistant, adjuvant vs. metastatic) and for different treatment modalities (systemic therapy, surgery, radiation therapy). This review aims to map the challenges that remain to be addressed before liquid biopsies can be widely used for cancer management.

Similar articles

See all similar articles

Cited by 11 articles

See all "Cited by" articles

Publication types

LinkOut - more resources

Feedback